Renal-Limited Atypical Hemolytic Uremic Syndrome: A Case Report (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #PUB124; "Initial renal biopsy demonstrated pseudo-crescentic GN, and the patient was treated empirically as ANCA-negative pauci-immune GN using cyclophosphamide alternating with rituximab...The patient was started on the C5 inhibitor Ravulizumab...Early recognition and initiation of complement inhibitor therapy may significantly improve renal outcomes and reduce dialysis dependence. widening of the subendothelial space is a classic ultrastructural hallmark of TMA"
Case report • Clinical • Atypical Hemolytic Uremic Syndrome • Complement-mediated Rare Disorders • Hematological Disorders • Nephrology • Pulmonary Disease • Renal Disease • Thrombocytopenia • CD46
|